[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coronary-artery-disease-progression\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coronary-artery-disease-progression":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,51,82,111,133,150,172,197],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":4},"100610783","phase-3-pre-empt-prospective-randomized-evaluation-and-management-of-premature-atherosclerosis-100610783",false,"NCT07232069","PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis","Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis","PRE-EMPT","Inclusion Criteria:\n\n1. Women aged 40-60 years; Men aged 30-50 years\n2. Willing and able to provide informed consent and comply with study procedures\n3. Smart phone user\n4. Use of highly effective contraception by females with reproductive potential.\n5. CAC score 1-99 in the screening study or entry through the known plaque pathway (with mild CAC or CAC\\\u003C100 if known; elevated CAC on baseline CCTA is not exclusionary in the known plaque arm)\n6. Diagnostic baseline CCTA with NCPV ≥10 mm3 as assessed by the central core lab\n\nExclusion Criteria:\n\n1. Clinical diagnosis of ASCVD including coronary artery disease (CAD), peripheral arterial disease (PAD) or cerebrovascular disease (CeVD)\n2. Current symptoms thought to be from CAD\n3. PREVENT ASCVD 10-year risk ≥5% (if known)\n4. Diabetes Mellitus (DM) as defined by any of the following: DM diagnosis in the medical record or HbA1C of 6.5% or greater. (if known)\n5. LDL-C ≥190mg\u002FdL (most recent, if known)\n6. HIV (if known)\n7. Severe liver disease or untreated Hepatitis C infection (if known)\n8. Pregnancy, lactation or intending to become pregnant during the study period of 2 years\n9. eGFR \\\u003C45mL\u002Fmin\u002F1.73m2 (if known)\n10. AST or ALT \\>1.5x the upper limit of normal (if known)\n11. BMI\\>40kg\u002Fm2 or unable to have a CCTA scan for any reason\n12. Allergy to iodinated intravenous contrast or other contraindication to CCTA\n13. Current or previous use of lipid lowering therapy or colchicine\n14. Known allergic reactions or sensitivity to the study intervention(s), including known intolerance or contraindication(s) to statin or colchicine, or long-term use of medications that are contraindicated with colchicine or rosuvastatin.\n15. Systemic cancer undergoing active treatment\n16. PREVENT ASCVD 10-year risk ≥5%\n17. eGFR \\\u003C45 ml\u002Fmin\u002F1.73m2 per baseline labs, (2021 CKD-EPI equation will be used if multiple options are available)\n18. Hemoglobin A1c ≥6.5% per baseline labs\n19. LDL-C ≥190mg\u002FdL per baseline labs\n20. Severe proximal coronary artery stenosis as determined by the central core lab (≥50% left main or ≥70% proximal major coronary artery stenosis)\n21. Known contraindication to follow-up CCTA (e.g., new IV contrast allergy discovered during the baseline CCTA)\n22. Individuals who are excluded based on any of these factors will be notified as to the reason for exclusion and encouraged to follow-up locally to address this medical issue with their treating physician.","ALL","30 Years","60 Years",{"count":21,"type":22},1500,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States. This clinical trial will test if screening and early treatment of mild heart disease works.\n\nPRE-EMPT will screen individuals at low 10-year risk of heart disease with heart disease risk factors to identify those who already have early cholesterol build up, also called \"plaque\", in their heart arteries. It consists of two phases:\n\n1. A Screening Study - Participants will be assessed for plaque by one or both of these scans.\n\n   * Coronary Artery Calcium (CAC) Scan: A CT scan that looks for calcium or plaque in heart arteries.\n   * Coronary CT Angiography (CCTA) Scan: A CT scan that uses contrast dye to create detailed 3D pictures of heart arteries to look for plaque.\n2. A Treatment Trial (approximately 1,500 participants) - Based on the results of the CCTA, participants may be randomized into a two-year trial to test medications aimed at reducing or stabilizing plaque. Participants will have a 1 in 4 chance of receiving only placebo, and a 3 in 4 chance of receiving at least one active medication. Participants will take two pills once a day-either both active medications, one active and one placebo, or both placebos.\n\n   * Rosuvastatin 20 mg: a cholesterol-lowering medicine\n   * Colchicine 0.5 mg: a medication that lowers inflammation\n\nEveryone in the trial will be given information and advice on heart-healthy diet and lifestyle.\n\nParticipants will have up to two in-person visits for the screening study, then phone visits for the Treatment Trial at the beginning, 3 months, 12 months and 24 months when they will also have an in-person visit for a CCTA Scan. Participants will have blood drawn using an at-home collection device mailed to their home at the beginning, 3 months, and end of the study.",[28,29,30,31],"Coronary Artery Disease Risk Factors Multiple","Coronary Artery Disease Progression","Prevention & Control","Premature Atherosclerosis",[33,34,35,36,37,38],"Prevention","Heart Disease Prevention","Family History of Heart Disease","At risk for heart disease","coronary artery calcium","non-calcified coronary plaque","NOT_YET_RECRUITING","2026-02-25",{"date":42,"type":43},"2026-02-27","ACTUAL",{"date":45,"type":22},"2026-07-01",{"date":47,"type":22},"2031-07",{"name":49,"class":50},"Duke University","OTHER",{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":70,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":4},"100611387","disease-characteristics-of-r-cad-100611387","NCT07239921","Disease Characteristics of R-CAD","Disease Characteristics of Rapidly Progressive Coronary Artery Disease (R-CAD): A Case-control Study","Inclusion Criteria:\n\nCase Group (R-CAD patients):\n\n1. 18 years of age or older, male or female.\n2. Negative results of urine or blood pregnancy test for females with childbearing potential (not post-menopausal or surgically sterile).\n3. Prior history of coronary revascularization (PCI or CABG).\n4. Receiving standard treatment for secondary prevention of AS-CAD after the latest coronary revascularization.\n5. Rapidly progressive myocardial ischemia leading to hospitalization and\u002For coronary revascularization:\n\n   1. Typical symptoms of angina (Canadian Cardiovascular Society \\[CCS\\] classification III-IV) and non-invasive evidence of myocardial ischemia; and\n   2. Occurred within 6 months of the latest ischemia-driven hospitalization and\u002For coronary revascularization.\n6. Rapidly progressive coronary lesions leading to myocardial ischemia:\n\n   1. Angiographic evidence of new-onset or worsened coronary de novo or restenotic lesions relevant to myocardial ischemia, and\n   2. Occurred within 6 months of the latest ischemia-driven coronary angiography and\u002For revascularization.\n\nControl Group (NR-CAD patients):\n\n1. 35 to 75 years old\\*, male or female. (\\* Based on the age distribution characteristics of patients who have been diagnosed as R-CAD.)\n2. Negative results of urine or blood pregnancy test for females with childbearing potential (not post-menopausal or surgically sterile).\n3. Currently, at 12±6 months after the latest PCI.\n4. Receiving standard treatment for secondary prevention of AS-CAD after the latest PCI.\n5. Coronary angiography and\u002For optical coherence tomography (OCT) performed during the index hospitalization.\n6. No evidence of rapidly progressive myocardial ischemia and coronary lesions, i.e., not fulfilling items 5) and 6) of the inclusion criteria for R-CAD.\n\nExclusion Criteria:\n\n1. Receiving immunosuppressive therapy within 6 months.\n2. Coronary restenosis due to mechanical factors (stent under-expansion, stent mal-apposition, stent rupture, et al).\n3. Other moderate to severe heart diseases (congenital heart disease, valvular heart disease, myocarditis, cardiomyopathy, pericardial diseases, pulmonary hypertension, heart failure, arrhythmia, et al).\n4. Active malignancy (diagnosed within 12 months or with ongoing requirement for treatment).\n5. Vital organ failure.\n6. Life expectancy \\\u003C 1 year.\n7. In pregnancy or breast-feeding, or with intention to be pregnant during the study period.\n8. Risk of non-compliance (history of drug addiction or alcohol abuse, et al).\n9. Previous enrollment in this study.\n10. Participation in another study within 30 days.\n11. Involvement in the planning and conduct of this study (applying to investigators, contract research organization staffs, study site staffs, et al).\n12. Any condition, which in the opinion of the investigators, would make it unsuitable for the patient to participate in this study.","18 Years",{"count":60,"type":22},52,"OBSERVATIONAL","The present case-control study is designed to investigate the disease characteristics of rapidly progressive coronary artery disease (R-CAD) by comparing the demographics, clinical features, lab results, imaging findings, and prior treatment between patients in the case group (approximately 34 patients with R-CAD) and those in the control group (approximately 18 patients with non-rapidly progressive coronary artery disease \\[NR-CAD\\]).",[64,29,65,66,67,68,69],"Coronary Artery Disease","Coronary Stenosis","Coronary Restenosis","Coronary Stent Occlusion","Myocardial Revascularization","Percutaneous Coronary Intervention",[64,65,66,68,69,71,72],"Disease Progression","Disease Attributes","2025-11-21",{"date":75,"type":43},"2025-11-28",{"date":77,"type":22},"2025-11",{"date":79,"type":22},"2026-10",{"name":81,"class":50},"Peking Union Medical College Hospital",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":89,"targetDuration":91,"studyType":61,"phases":4,"briefSummary":92,"conditions":93,"keywords":99,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},"100581061","clinical-features-current-treatment-and-clinical-outcomes-in-patients-with-inr-cad-a-cohort-study-100581061","NCT06845410","Clinical Features, Current Treatment and Clinical Outcomes in Patients With INR-CAD: a Cohort Study","Clinical Features, Current Treatment and Clinical Outcomes in Patients With Inflammation-associated Non-rapidly-progressive Coronary Artery Disease (INR-CAD): a Cohort Study","Inclusion criteria\n\n1. 18 years of age or older, male or female.\n2. Negative results of urine or blood pregnancy test for females with childbearing potential (not post-menopausal or surgically sterile).\n3. Meeting the clinical diagnostic criteria for INR-CAD, including: (1) Angiographic evidence of coronary lesions (≥ 50% diameter stenosis, de novo or restenotic); (2) Evidence of chronic inflammation within 24 months: (A) Positive inflammatory markers (erythrocyte sedimentation rate \\[ESR\\], high-sensitivity C-reactive protein \\[hs-CRP\\], interleukin-6 \\[IL-6\\], tumor necrosis factor-alpha \\[TNF-α\\], et al; at least twice, ≥ 12 weeks apart), or (B) Positive autoantibodies (at least twice, ≥ 12 weeks apart), or (C) Established diagnosis of chronic inflammatory diseases (autoimmune disease, systemic vasculitis, psoriasis, tuberculosis, et al), or (D) Receiving immunosuppressive therapy (glucocorticoids, immunosuppressive agents, et al).\n4. NOT meeting the clinical diagnostic criteria for IR-CAD, including: (1) Hospitalization due to myocardial ischemia, including: (A) Typical symptoms of angina (Canadian Cardiovascular Society \\[CCS\\] III-IV), and (B) Non-invasive evidence of myocardial ischemia; (2) Angiographic evidence of new or worsened coronary lesions (de novo or restenotic) considered relevant to myocardial ischemia, which occurred: (A) Within 6 months of last coronary angiography in any patients, or (B) Within 12 months of last coronary angiography in patients receiving immunosuppressive therapy within 24 months.\n5. Received, or are receiving, or will receive the 24-month clinical follow-up defined by the clinical follow-up protocol for INR-CAD.\n\nExclusion Criteria:\n\n1. Other moderate to severe heart diseases (congenital heart disease, valvular heart disease, myocarditis, cardiomyopathy, pericardial diseases, pulmonary hypertension, heart failure, arrhythmia, et al).\n2. Active malignancy (diagnosed within 12 months or with ongoing requirement for treatment).\n3. Vital organ failure.\n4. Life expectancy \\\u003C 1 year.\n5. In pregnancy or breast-feeding, or with intention to be pregnant during the study period.\n6. Risk of non-compliance (history of drug addiction or alcohol abuse, et al).\n7. Previous enrollment in this study.\n8. Participation in another study within 30 days.\n9. Involvement in the planning and conduct of this study (applying to investigators, contract research organization staffs, study site staffs, et al).\n10. Any condition, which in the opinion of the investigators, would make it unsuitable for the patient to participate in this study.",{"count":90,"type":22},120,"24 Months","This is a cohort study to investigate the clinical features, current treatment and clinical outcomes in patients with inflammation-associated non-rapidly-progressive coronary artery disease (INR-CAD).",[64,29,94,95,96,97,98],"Coronary Artery Stenosis","Coronary Artery Restenosis","Inflammation","Inflammatory Disease","Inflammation Vascular",[64,100,96],"Progression, Disease","RECRUITING","2025-11-16",{"date":104,"type":43},"2025-11-19",{"date":106,"type":43},"2025-04-01",{"date":108,"type":22},"2026-12",{"name":81,"class":50},1,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":118,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":122,"conditions":123,"keywords":124,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":127,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":110},"100516647","disease-characteristics-of-ir-cad-a-case-control-study-100516647","NCT06007248","Disease Characteristics of IR-CAD: a Case-control Study","Disease Characteristics of Inflammation-associated Rapidly-progressive Coronary Artery Disease (IR-CAD): a Case-control Study","Inclusion Criteria:\n\nCase group (IR-CAD patients):\n\n1. 18 years of age or older, male or female.\n2. Negative results of urine or blood pregnancy test for females with childbearing potential (not post-menopausal or surgically sterile).\n3. Prior history of coronary revascularization (PCI or coronary artery bypass graft \\[CABG\\]).\n4. Receiving standard treatment for secondary prevention of AS-CAD after the last coronary revascularization.\n5. Hospitalization due to rapidly-progressive myocardial ischemia:\n\n   * Typical symptoms of angina (Canadian Cardiovascular Society \\[CCS\\] III-IV) and non-invasive evidence of myocardial ischemia; and\n   * Occurred within 6 months or occurred on immunosuppressive therapy within 12 months of the last coronary revascularization.\n6. Angiographic evidence of new coronary lesions (de novo stenosis or restenosis) considered to be relevant to myocardial ischemia.\n7. Evidence of inflammation:\n\n   * At least one of the indexes indicating active inflammation has ever been elevated (ESR, high-sensitivity C-reactive protein \\[hs-CRP\\], interleukin \\[IL\\]-6, tumor necrosis factor \\[TNF\\]-α, ferritin, et al); or\n   * Established diagnosis of systemic autoimmune disease or systemic vasculitis; or\n   * Receiving immunosuppressive therapy.\n\nControl group (AS-CAD patients):\n\n1. ≥ 45 and \\\u003C 65 years of age (based on the age distribution of the patients currently enrolled in the IR-CAD cohort study), male or female.\n2. Negative results of urine or blood pregnancy test for females with childbearing potential (not post-menopausal or surgically sterile).\n3. Currently, 12±6 months after the last PCI.\n4. Receiving standard treatment for secondary prevention of AS-CAD after the last PCI.\n5. Coronary angiography and\u002For optical coherence tomography (OCT) performed during the present hospitalization.\n6. No evidence of rapidly-progressive myocardial ischemia, which is defined as follows:\n\n   * Typical symptoms of angina (Canadian Cardiovascular Society \\[CCS\\] III-IV) and non-invasive evidence of myocardial ischemia; and\n   * Occurred within 6 months or occurred on immunosuppressive therapy within 12 months of the last PCI.\n7. No angiographic evidence of new coronary lesions (de novo stenosis or restenosis) considered to be relevant to myocardial ischemia.\n\nExclusion Criteria:\n\nCase group (IR-CAD patients):\n\n1. Coronary restenosis due to mechanical factors (stent under-expansion, stent mal-apposition, stent rupture, et al).\n2. Other moderate to severe heart diseases (congenital heart disease, valvular heart disease, myocarditis, cardiomyopathy, pericardial diseases, pulmonary hypertension, heart failure, arrhythmia, et al).\n3. Active acute or chronic infection (human immunodeficiency virus \\[HIV\\], tuberculosis, et al).\n4. Active malignancy (diagnosed within 12 months or with ongoing requirement for treatment).\n5. Vital organ failure.\n6. Life expectancy \\\u003C 1 year.\n7. Contraindications for or intolerance to treatment for secondary prevention of AS-CAD, contrast agents, glucocorticoids, immunosuppressive agents.\n8. In pregnancy or breast-feeding, or with intention to be pregnant during the study period.\n9. Risk of non-compliance (history of drug addiction or alcohol abuse, et al).\n10. Previous enrollment in this study.\n11. Participation in another study within 30 days.\n12. Involvement in the planning and conduct of this study (applying to investigators, contract research organization staffs, study site staffs, et al).\n13. Any condition, which in the opinion of the investigators, would make it unsuitable for the patient to participate in this study.\n\nControl group (AS-CAD patients):\n\nThe same as those for the case group (IR-CAD patients).","45 Years","64 Years",{"count":121,"type":22},30,"The present case-control study is designed to investigate the disease characteristics of IR-CAD by comparing the demographics, clinical features, lab results, imaging findings, and prior treatment between 20 patients with IR-CAD and 10 patients with AS-CAD.",[64,94,95,29,96,97,98],[64,125,100,96,126],"Coronary Revascularization","Characteristics Disease",{"date":104,"type":43},{"date":129,"type":43},"2023-11-02",{"date":131,"type":22},"2026-09",{"name":81,"class":50},{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":140,"targetDuration":91,"studyType":61,"phases":4,"briefSummary":142,"conditions":143,"keywords":144,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":149,"locationsCount":110},"100505364","efficacy-and-safety-of-comprehensive-treatment-in-patients-with-ir-cad-a-self-controlled-cohort-study-100505364","NCT05860400","Efficacy and Safety of Comprehensive Treatment in Patients With IR-CAD: a Self-controlled Cohort Study","Efficacy and Safety of Comprehensive Treatment in Patients With Inflammation-associated Rapidly-progressive Coronary Artery Disease (IR-CAD): a Self-controlled Cohort Study","Inclusion Criteria:\n\n1. Fulfilling all the following criteria before initiation of comprehensive treatment:\n\n   1.1 18 years of age or older, male or female.\n\n   1.2 Negative result of urine or blood pregnancy test for females with childbearing potential (not post-menopausal or surgically sterile).\n\n   1.3 Prior history of coronary revascularization (percutaneous coronary intervention \\[PCI\\] or coronary artery bypass graft \\[CABG\\]).\n\n   1.4 Receiving standard treatment for secondary prevention of atherosclerotic coronary artery disease (AS-CAD) after the last coronary revascularization.\n\n   1.5 Hospitalization due to rapidly-progressive myocardial ischemia:\n   * Typical symptoms of angina (Canadian Cardiovascular Society \\[CCS\\] III-IV) and non-invasive evidence of myocardial ischemia; and\n   * Occurred within 6 months or occurred on immunosuppressive therapy within 12 months of the last coronary revascularization.\n\n   1.6 Angiographic evidence of new coronary lesions (de novo stenoses or restenoses):\n   * Occurred after the last coronary revascularization; and\n   * Related to myocardial ischemia (location, extent, severity, et al).\n\n   1.7 Evidence of inflammation:\n   * At least one of the markers indicating active inflammation has ever been elevated (erythrocyte sedimentation rate \\[ESR\\], high-sensitivity C-reactive protein \\[hs-CRP\\], interleukin \\[IL\\]-6, tumor necrosis factor \\[TNF\\]-α, ferritin, et al); or\n   * Established diagnosis of systemic autoimmune disease or systemic vasculitis; or\n   * Receiving immunosuppressive therapy.\n2. Receiving comprehensive treatment, including ischemia-driven PCI which was performed no earlier than 40 days of the initiation of immunosuppressive therapy.\n\nExclusion Criteria:\n\n1. Coronary restenosis due to mechanical factors (stent under-expansion, stent mal-apposition, stent rupture, et al).\n2. Other moderate to severe heart diseases (congenital heart disease, valvular heart disease, myocarditis, cardiomyopathy, pericardial diseases, pulmonary hypertension, heart failure, arrhythmia, et al).\n3. Active acute or chronic infection (human immunodeficiency virus \\[HIV\\], tuberculosis, et al).\n4. Active malignancy (diagnosed within 12 months or with ongoing requirement for treatment).\n5. Vital organ failure.\n6. Life expectancy \\\u003C 1 year.\n7. Contraindications for or intolerance to treatment for secondary prevention of AS-CAD, contrast agents, glucocorticoids, immunosuppressive agents.\n8. In pregnancy or breast-feeding, or with intention to be pregnant during the study period.\n9. Risk of non-compliance (history of drug addiction or alcohol abuse, et al).\n10. Previous enrollment in this study.\n11. Participation in another study within 30 days.\n12. Involvement in the planning and conduct of this study (applying to investigators, contract research organization staffs, study site staffs, et al).\n13. Any condition, which in the opinion of the investigators, would make it unsuitable for the patient to participate in this study.",{"count":141,"type":22},39,"This is a self-controlled cohort study to evaluate the efficacy and safety of comprehensive treatment in patients with inflammation-associated rapidly-progressive coronary artery disease (IR-CAD) by comparing the study endpoints before treatment with those after treatment in the same group of patients.",[64,94,95,29,96,97,98],[64,125,100,96],{"date":104,"type":43},{"date":147,"type":43},"2023-05-17",{"date":131,"type":22},{"name":81,"class":50},{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":157,"enrollmentInfo":158,"targetDuration":160,"studyType":61,"phases":4,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":110},"100499480","plaque-reversal-with-early-aggressive-lipid-lowering-therapy-100499480","NCT05783804","Plaque Reversal With Early, Aggressive Lipid Lowering Therapy","EAGLE","Inclusion Criteria:\n\n* Diagnosed with heterozygous familial hypercholesterolemia\n* Adult between 18 and 50 years old\n* LDL cholesterol levels above 100 mg\u002Fdl (\\>2.6 mmol\u002FL) at inclusion\n\nExclusion Criteria:\n\n* Renal insufficiency, defined as eGFR \\\u003C 30 ml\u002Fmin\n* History of atherosclerotic cardiovascular events\n* Atrial fibrillation\n* Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator\n* Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.","50 Years",{"count":159,"type":22},60,"40 Weeks","This study evaluates whether plaques in young patients with familial hypercholesterolemia (aged below 50 years) are susceptible to significant plaque regression with early, intensive lipid lowering therapy.",[29],"2025-09-30",{"date":165,"type":43},"2025-10-02",{"date":167,"type":43},"2022-07-07",{"date":169,"type":22},"2027-04",{"name":171,"class":50},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":110},"100519171","natural-history-of-coronary-atherosclerosis-100519171","NCT06040073","Natural History of Coronary Atherosclerosis","Natural History of Coronary Atherosclerosis Based on Multimodal Imaging and Physiological Fusion Techniques (NASCENT)","NASCENT","Inclusion Criteria:\n\n* General Inclusion Criteria:\n\n  1. Age ≥18 years\n  2. Acute myocardial infarction ≤ 45 days\n  3. Planned coronary angiography examination or potential interventional treatment\n* Angiographic Inclusion Criteria:\n\n  1. The presence of at least 1 non-flow-restricting lesion (visually estimated diameter stenosis: 30%-80%; QFR \\> 0.80) in any non-infarct related artery with RVD ≥2.5 mm by visual assessment\n\nExclusion Criteria:\n\n* General exclusion Criteria:\n\n  1. Cardiogenic shock\n  2. Pregnant or woman of child-bearing potential\n  3. Life expectancy less than 1 year for non-cardiac causes\n  4. Unable to tolerate contrast agents or anticoagulant\u002Fantiplatelet therapy\n  5. Prior CABG or planned CABG\n* Angiographic exclusion Criteria:\n\n  1. Poor angiographic image quality precluding vessel contour detection or with suboptimal contrast opacification, branch ostium cannot be shown clearly, severe overlap in the stenosed segment or severe tortuosity of any interrogated vessel deemed not amenable to QFR or RWS measurement\n  2. An interrogated lesion require surgical bypass grafting\n  3. Unable to judge culprit lesion or infarct-related artery according to current evidence",{"count":181,"type":22},125,"The present study sought to explore the predictive value of radial wall strain (RWS, derived solely from angiograms) for coronary artery lesion progression compared with lesion vulnerability assessed by optical coherence tomography (OCT). The lesion progression at 1 year was defined as an increase of ≥20% in diameter stenosis based on quantitative coronary angiography (QCA) evaluation.",[29,184,185,186],"Radial Wall Strain","Atherosclerotic Lesion","Optical Coherence Tomography","2024-11-04",{"date":189,"type":43},"2024-11-06",{"date":191,"type":43},"2024-07-07",{"date":193,"type":22},"2026-12-31",{"name":195,"class":196},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":205,"enrollmentInfo":206,"targetDuration":208,"studyType":61,"phases":4,"briefSummary":209,"conditions":210,"keywords":213,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":110},"100421820","prior-cabg-patients-evaluated-for-saphenous-vein-graft-dysfunction-and-progression-of-coronary-artery-disease-100421820","NCT04772768","Prior CABG Patients Evaluated for Saphenous VeIn grAft DysfUnction and Progression of Coronary arTery Disease","Patients With Prior Coronary Artery Bypass Graft Surgery Evaluated for Saphenous VeIn grAft DysfUnction and Progression of Coronary arTery Disease","VIADUCT","Inclusion Criteria:\n\n* Prior coronary artery bypass grafting\n* One or more saphenous vein grafts\n* Recurrent angina symptoms\n\nExclusion Criteria:\n\n* \\\u003C18 years of age\n* ≥ 90 years of age\n* Cardiogenic shock\n* Pregnancy\n* Failure to provide informed consent","90 Years",{"count":207,"type":22},500,"5 Years","This is a multi-center, observational cohort study including patients with prior coronary artery bypass grafting (CABG) and ≥1 saphenous vein grafts (SVG) presenting with recurrent ischemic symptoms. Objective: to investigate the clinical outcomes in patients with prior CABG evaluated for bypass graft failure and progression of native coronary artery disease (CAD). Follow-up will be collected through national registry databases, electronic medical patient records and standardized telephonic assessment at 3 and 5 years follow-up.",[211,212,29],"Recurrent Angina After Coronary Artery Bypass Graft","Graft Failure",[214,215,216,217],"Coronary Artery Bypass Grafting","Recurrent angina","Saphenous vein graft dysfunction","Advanced coronary artery disease","2023-05-30",{"date":220,"type":43},"2023-06-02",{"date":222,"type":43},"2019-08-23",{"date":224,"type":22},"2029-07-23",{"name":226,"class":50},"Amsterdam UMC, location VUmc"]